Literature DB >> 15887156

Treatment for pancreatic cancer: current therapy and continued progress.

A Craig Lockhart1, Mace L Rothenberg, Jordan D Berlin.   

Abstract

In the last decade, continued efforts in pancreas cancer research have led to the development of new, more effective therapies. Additionally, progress in understanding the molecular processes underlying the development and progression of this disease provides hope for the development of more effective treatment strategies. Recent clinical trials have provided reason for hope that novel chemotherapy combinations and molecularly targeted agents will lead to improved clinical outcomes for patients with this disease. This article will summarize the data that has led to the current standards of therapy for patients with resectable and advanced pancreatic cancer and review new treatment strategies for this disease.

Entities:  

Mesh:

Year:  2005        PMID: 15887156     DOI: 10.1053/j.gastro.2005.03.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  52 in total

Review 1.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer.

Authors:  Clare Hoskins; Mehdi Ouaissi; Sofia Costa Lima; Woei Ping Cheng; Inês Loureirio; Eric Mas; Dominique Lombardo; Anabela Cordeiro-da-Silva; Ali Ouaissi; Paul Kong Thoo Lin
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

3.  Surgery for recurrent pancreatic ductal adenocarcinoma.

Authors:  Jörg Kleeff; Carolin Reiser; Ulf Hinz; Jeannine Bachmann; Jürgen Debus; Dirk Jaeger; Helmut Friess; Markus W Büchler
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

4.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer.

Authors:  Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

5.  Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.

Authors:  Yasuhiro Fujino; Tetsuya Sakai; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2008-03-29       Impact factor: 7.527

6.  Three cases of locally advanced pancreatic cancer successfully treated with chemoradiation and chemotherapy.

Authors:  Masashi Taguchi; Yoshikuni Nagashio; Yasuyuki Kihara; Masaaki Hiura; Shintaro Abe; Mitsuyoshi Yamamoto; Masaru Harada
Journal:  Clin J Gastroenterol       Date:  2010-06-05

7.  Bayesian Semi-parametric Analysis of Semi-competing Risks Data: Investigating Hospital Readmission after a Pancreatic Cancer Diagnosis.

Authors:  Kyu Ha Lee; Sebastien Haneuse; Deborah Schrag; Francesca Dominici
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-02-01       Impact factor: 1.864

8.  Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Hee Jeong Kim; Eliot M Rosen; Sivanesan Dakshanamurthy; Riccardo Rondanin; Riccardo Baruchello; Giuseppina Grisolia; Simoni Daniele; Insoo Bae
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

9.  Distal Pancreatectomy with En Bloc Resection of the Celiac Axis with Preservation or Reconstruction of the Left Gastric Artery in Patients with Pancreatic Body Cancer.

Authors:  Takafumi Sato; Akio Saiura; Yosuke Inoue; Yu Takahashi; Junichi Arita; Nobuyuki Takemura
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

10.  The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.

Authors:  Bo Chen; Ming Xu; Hui Zhang; Ming-zheng Xu; Xu-jing Wang; Qing-he Tang; Jian-ying Tang
Journal:  DNA Cell Biol       Date:  2015-08-18       Impact factor: 3.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.